Bionova Capital
Peter Villax is the Chairman of Bionova Capital. He joined Hovione in 1982 as a computer programmer and led Hovione’s computerization. He then switched to pharmaceutical development in 1990 and soon became interested in in pulmonary delivery. His disposable dry-powder inhaler TwinCaps, licensed to Daiichi Sankyo for the delivery of Influenza drug Inavir®, continues to be the only commercial device of its kind in the world, and has helped Daiichi Sankyo become the market leader in influenza products in Japan. He acquired significant experience as an inventor of devices, as a patentholder and as a licensor of technology patents.
In 2013, he was involved in a 7-figure royalty monetization deal with a US-based financial company, under which Hovione sold its future licensing income streams.
This person is not in the org chart
This person is not in any teams
Bionova Capital
Bionova Capital, previously known as Hovione Capital, is a healthcare-focused venture capital firm, investing in early-stage life science companies. It was founded in 2015 by the shareholders of Hovione, one of the largest pharmaceutical companies in Portugal, with manufacturing and research operations in the USA, Ireland, China, and Portugal. Bionova Capital invests in groundbreaking therapeutics, MedTech, and digital health startups across Europe.